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TheBackground: Dilated cardiomyopathy is associated with a progressive decrease in
cardiac function, leading to end-stage heart failure. We aimed to stop this process by
mechanically constraining the heart with a new, compliant textile mesh.
Methods: In 16 male Munich minipigs (50  7 kg), dilated cardiomyopathy with
congestive heart failure was induced through 4 weeks of rapid ventricular pacing
(220 beats/min). In the early-mesh group (n  8), a polyvinylidene fluoride mesh
was positioned around both ventricles before pacing was started. In the other group
(n 8), experimental dilated cardiomyopathy through rapid pacing was induced (no
mesh). After mesh grafting, rapid pacing was continued (late mesh).
Results: Rapid pacing in the no-mesh group (control group) significantly de-
creased both systolic (cardiac output, peak systolic pressure, and the derivative
of pressure increase [dP/dtmax]) and diastolic (minimum rate of pressure rise
[dP/dtmin] and left ventricular end-diastolic pressure) variables, whereas these
variables remained almost unchanged in the early-mesh group. In the late-mesh
group the passive-elastic constraint not only prevented further deterioration but
even exerted reverse remodeling to some extent (dP/dtmax and left ventricular
end-diastolic pressure, P  .05).
Conclusions: Ventricular constraint with the new mesh seems to be a prophylactic
and therapeutic option in cardiac insufficiency caused by ventricular dilation. This
passive-elastic cardioplasty induced reverse remodeling of dilated hearts and sig-
nificantly improved diastolic and systolic ventricular function.
Cardiac failure is one of the most common diseases in the Western world. Thenumber of patients with myocardial insufficiency has tripled in the past 20years and is estimated to amount to 1%.1
This increase is caused by improved conservative therapeutic options, as well as
increasing numbers of elderly persons. Both heart transplantation and left ventric-
ular (LV) assist devices are promising therapeutic options. However, a variety of
complications and contraindications exist.2 Except for problems with biologic
compatibility and immense costs, long waiting lists underline the problem with
suited heart donors. On the other hand, LV assist devices present a large technical
effort. Hence one could conclude that these therapeutic tools will not be able to
supply the growing number of patients adequately under economic, numeric, and
medical aspects.
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port, the latissimus dorsi muscle was wrapped around the
insufficient cardiac muscle as a cardiomyoplasty.3,4 This
procedure has already been applied in more than 1000
patients, yet it has not become a clinical standard. Although
the question of whether dynamic or adynamic cardiomyo-
plasty would be superior remained unanswered,5,6 further
ventricular dilation could be avoided because of the “gir-
dling” effect.5 Postoperatively, the patient status was im-
proved by one to two New York Heart Association classes.7
The girdling effect seems to limit the diastolic volume
and thus improves systolic function. In consequence, appli-
cation of a passive external device could represent a new
direction in the therapy of myocardial insufficiency.5
Not surprisingly, static support devices have been devel-
oped.8,9 New synthetic fibers were designed and other tech-
niques to manufacture better-suited mesh grafts were devel-
oped to further improve such cardiac binding.
Preclinical studies have shown that constraining devices
can provide end-diastolic support by (1) reducing mechan-
ical wall stress, (2) improving function, and (3) reversing
cardiac remodeling.10,11 Thus far, those devices have been
implanted worldwide in more than 130 patients with dilated
cardiomyopathy (DCM) with or without concomitant car-
diac surgery, improving the patient’s functional status.11
Therefore, passive ventricular constraints are suggested as a
very promising tool for the treatment of heart failure and
DCM.12
This study investigated the applicability of a new, elastic,
textile mesh made of polyvinylidene fluoride fibers13 as a
cardiac constraint. We determined in pigs whether a passive-
elastic cardioplasty improves ventricular function after es-
tablished heart failure and whether it prevents the develop-
ment of tachycardia-induced ventricular dilatation.
Experiments were performed on a total of 21 pigs. In a
prophylactic group, mesh grafting was performed before the
onset of 4 weeks of rapid pacing. In a therapeutic group,
heart failure was induced through 4 weeks of rapid pacing
without the mesh, such that this group served as controls.
Then the mesh was implanted, and rapid pacing was con-
tinued for another 4 weeks. The hemodynamic effects of
rapid pacing and of the mesh were monitored throughout the
individual 4-week protocols.
Materials and Methods
The study was performed on anesthetized male Munich minipigs
(49.5  7.0 kg of body weight). The animals were randomly
assigned to one of two groups. Of a total of 21 pigs, 5 died because
of ventricular fibrillation, pneumothorax, or massive bleeding. The
study was performed according to the “Guidelines for the Care and
Use of Laboratory Animals” (National Institutes of Health, 1985),
and the study was approved by the bioethical committee of the
district of Duesseldorf, Germany.
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Thus far, a polyethylene terephthalate was fabricated into a mul-
tifilament compliant mesh knit (CorCap; Acorn, St Paul, Minn) for
permanent implantation. In the present study, a mesh was chosen
that was made of polyvinylidene fluoride (PVDF) fibers (FEG Co,
Aachen, Germany). PVDF as a polymer has been commonly used
in the clinic for more than 10 years.13 PVDF sutures provided
greater breaking strengths in tendons than in those repaired with
polypropylene sutures,14 seemed to be more biostable than
polypropylene sutures in the long term,13,15 demonstrated minimal
tissue response in vivo, and can be sterilized with - or -radiation
and therefore can reduce dependence on ethylene oxides and
chlorofluorohydrocarbons.16 On the other hand, histologic analysis
of explants found no inflammatory cells in the tissue around either
PVDF or polypropylene sutures.16
PVDF mesh is already in use for abdominal hernia repair,
where it proved to be advantageous because of improved biosta-
bility, lowered bending stiffness, and minimum tissue response,17
and as scaffolds for tissue regeneration in the esophagus.18
The CorCap mesh is described to be compliant. The PVDF
mesh used in this study is compliant as well, but because of its
weaving technique, it also had elastic properties, making it a
passive-elastic epicardial constraint. Yet we cannot provide actual
mechanical data.
Anesthesia
Premedication consisted of ketamine (0.2 mg/kg administered
intramuscularly), azaperone (0.08 mg/kg administered intramus-
cularly), and atropine (0.02 mg/kg administered intramuscularly).
After 15 minutes, thiopental (3 mg/kg administered intravenously),
pancuronium bromide (0.1 mg/kg), and fentanyl dihydrogencitrate
(5 g/kg) were administered. Anesthesia was maintained with
enflurane, and N2O2 was established.
General Surgery
A left lateral thoracotomy was performed in the early-mesh and
no-mesh hearts of the late-mesh group. Lidocaine (2%; 5 mL) was
infused to prevent arrhythmia. After resection of the thymus gland,
the pericardium was opened to expose the anterior wall of the
heart. Heparin (1000-2000 IE) was given according to the body
weight. Through the LV anterior wall, a Konigsberg catheter was
implanted to assess the intraventricular pressure (LV pressure;
P4.0X6-S-CK; Konigsberg Instruments, Pasadena, Calif). Then a
bipolar pacing electrode (KY 66 II; Osypka Co, Rheinfelden,
Germany) was placed into the right ventricle and was secured to
the right ventricular wall. An electrocardiographic electrode lo-
cated on the LV pressure catheter was fixed at the left atrium. For
measuring cardiac output (CO), a flow probe was placed around
the pulmonary artery (Triton ART2 Flow Probe, TRI-200-307-K/
L-Y50CM-CSTY-KB; Konigsberg Instruments). All connecting
wires were placed subcutaneously through the back of the animal,
and the pacemaker electrode was connected with the 1-cavity
pacemaker (Pace 101H, Osypka Co).
In contrast to the early-mesh group, the mesh in the late-mesh
group was implanted after sternotomy at the time of reoperation.
The graft was positioned around both ventricles and secured with
sutures on the atrioventricular level, leaving the apex uncovered
(Figure 1). The anterior part of the mesh was closed with a running
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was chosen not only to increase the end-diastolic pressure in the
early-mesh group but to also reduce the end-diastolic pressure by
a maximum of 5 mm Hg without affecting the peak systolic
pressure in the late-mesh group. In all animals, the pericardium
was resected, and the thorax was closed in accordance with local
Figure 1. Schematic of the mesh after implantation. Neither the
apex nor the auricles were covered by the mesh. The basal
portion of the mesh was secured on the atrioventricular level.
Figure 2. Experimental protocol. In these animals mes
(early-mesh group). Rapid pacing was initiated after hemo
The Journal of Thoracic ancustom. Antibiotic prophylaxis was given to all animals with
lincomycin (2 · 20 mg/kg administered intravenously).
Experimental Protocol
The animals were randomly assigned to either the early-mesh or
the late-mesh group.
Early-mesh group (n  8). For induction of DCM, 24-day
rapid pacing was started after an average of 4.1 days of recovery
after surgical intervention (Figure 2). This prophylactic protocol
was performed to demonstrate the effects of a textile mesh (ie, of
a passive-elastic epicardial constraint) on the development of
DCM.
Late-mesh group (n  8). In the first part of the protocol,
rapid pacing of hearts without mesh was started 5.0 days after
surgical intervention (no-mesh group). DCM was induced through
rapid pacing and was considered established when CO and the
derivative of pressure increase (dP/dtmax) had decreased to 60% of
baseline values (on average, 22.1 days). Hence these no-mesh
animals served as control animals for the early-mesh group. After
median sternotomy, the mesh was implanted as above (late-mesh
group). A 21.5-day rapid pacing period was initiated after 3.7 days
of recovery after reoperation (Figure 3). This therapeutic protocol
was thought to demonstrate the effects of further rapid pacing on
a heart with established DCM that was supported with a passive
epicardial constraint.
In both parts of the protocol, rapid pacing was started at 140
beats/min. After 2 to 3 days, the pacing rate was increased to a
maximum of 220 beats/min. After completion of either protocol,
the mesh and the myocardium were examined both macroscopi-
cally and histologically.
Data Acquisition and Statistics
The following variables were assessed: CO and LV pressure. From
the LV pressure signal, peak systolic pressure, end-diastolic pres-
sure, maximum pressure increase and decrease, and heart rate
(HR) were derived.
fting was performed already during the first operationh gra
dynamic stabilization. OP, Operation; pm, pacemaker.
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tively, at the start of pacemaker use, at maximum pacing rate, after
25% of maximum stimulation, after 50% of maximum stimulation
(T50%), after 75% of maximum stimulation (T75%), and at the
day of end operation.
Statistical analysis was performed with a 2-way analysis of
variance (SPSS 11.5 for Windows; SPSS Inc, Chicago, Ill). If
significant differences in mean values were detected, individual
mean values were compared by Fisher least-significant-difference
post-hoc tests.
Results
Comparison of the Early-Mesh Group With the
No-Mesh Group
Systolic variables, such as CO, LV peak pressure (LVPmax),
and the derivative of pressure increase (dP/dtmax) were
significantly higher in the no-mesh group compared with in
the early-mesh group (Table 1). HR and diastolic variables,
such as early (dP/dtmin) and late (LVPed) relaxation, were
not significantly different.
Because of the given pacing rate, HR did not differ
between groups during the entire protocol. Systolic mea-
sures (CO, LVPmax, and dP/dtmax) in the early-mesh hearts
only slightly decreased or were maintained during the pro-
tocol, whereas the no-mesh hearts deteriorated more dras-
tically (P  .05): CO by only 1.4  0.2 L/min versus
4.1  0.3 L/min (mean  standard error of the mean;
Figure E1, A); LVPmax by 9  1 mm Hg versus 39 
3 mm Hg (Figure E1, B); and dP/dtmax by 288  30 mm
Hg/s versus 1350  122 mm Hg/s (Figure E1, C).
Early diastolic relaxation deteriorated significantly in the
groups with and without support over time: in the early-
Figure 3. Experimental protocol. The hearts of these an
was established (no-mesh group). The mesh was posi
rapid pacing was continued. OP, Operation; pm, pacemmesh group from 1976  155 mm Hg/s to 1488  144 mm
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110 mm Hg/s. At the end of the protocol, the differences
between the groups were significant (Figure E2, A).
The LV end-diastolic pressures at the onset of the pro-
tocol were not significantly different. Despite the increased
LV end-diastolic pressures in the supported hearts com-
pared with the no-mesh hearts (11  3 vs 5  2 mm Hg),
LV end-diastolic pressure remained unchanged during pac-
ing (11  3 vs 10  2 mm Hg) but significantly increased
in the no-mesh hearts (5  2 vs 24  2 mm Hg), also
reflecting ventricular insufficiency (Figures E2, A, and E3, A).
It is remembered that rapid pacing in the no-mesh group
(control group) lasted only about 22 days, whereas it lasted
about 24 days in the early-mesh group. Thus, the deterio-
ration in the control animals will very likely be
underestimated.
were paced after the first operation until heart failure
d during a reoperation (late-mesh group). Thereafter,
r.
TABLE 1. Baseline values of the early-mesh group and the
no-mesh group
Early-mesh
group
No-mesh
group P value
Heart rate (1/min) 91 5 103 8 NS
Cardiac output (L/min) 6.4 0.4 7.8  0.6 .012
LVPmax (mm Hg) 88  6 110 7 .048
dP/dtmax (mm Hg/s) 1763 189 2625 149 .005
dP/dtmin (mm Hg/s) 1976 155 1778 202 NS
LVPed (mm Hg) 11  3 5  2 NS
The systolic variables of the hearts with mesh were significantly smaller
compared with those of the no-mesh hearts, whereas the diastolic measures
exhibited no significant differences. NS, Not significant; LVPmax, left ventric-
ular peak pressure; dP/dt , derivative of pressure increase; dP/dt , deriv-imals
tione
akemax min
ative of pressure decrease; LVPed, left ventricular end-diastolic pressure.
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Spontaneous HR did not significantly differ between the
first operation and reoperation (Table 2). CO at reoperation
was reduced by 11% compared with baseline CO at the first
operation, whereas LVPmax was moderately increased by
6%. However, the contractile state and both diastolic mea-
sures significantly demonstrated cardiac insufficiency: dP/
dtmax was decreased by 28%, dP/dtmin was decreased by
29%, and LV end-diastolic pressure was increased by
183%.
Macroscopic intraoperative findings showed severe dila-
tion and massive loss of contractile function in all 8 hearts.
Because the same pacing rate was chosen in both proto-
cols, HR did not differ between groups. CO at the end of the
protocol in the no-mesh hearts was decreased by 4.1
L/min, and that in the late-mesh hearts was decreased by
only 0.9 L/min (Figure E4, A). Likewise, both other systolic
measures (LVPmax and dP/dtmax) in the no-mesh hearts
decreased significantly during the protocol (30% and 50%;
Figure E4, B and C). After reoperation and mesh grafting,
LVPmax was maintained (3%), and dP/dtmax even in-
creased (36%) in these hearts.
During rapid pacing, early diastolic relaxation was de-
creased in the no-mesh hearts (42%, P  .05), whereas it
increased in the late-mesh hearts (20%; Figure E3, A).
Similarly, LV end-diastolic pressure had increased during
pacing by 380% (P  .05) in the no-mesh hearts, and this
measure of late relaxation was decreased in the late-mesh
hearts by 50% (P  .05; Figure E3, B).
Histology
In accordance with the literature, only minimal tissue re-
sponse and no inflammatory cells in the tissue around the
mesh were found. In addition, adhesion to the surrounding
tissue was moderate, such that the mesh could be removed
from the epicardium.
Discussion
Myocardial insufficiency is frequently the consequence of
ventricular dilation. Therapeutic options are aimed to stop
or even reverse this process.19 In the past, the ventricular
size was surgically reduced. However, recurrence of ven-
tricular dilation and myocardial failure has led to the aban-
donment of this option.20,21
Among other techniques, pacemaker-stimulated skeletal
muscle was used to wrap the ventricle.22,23 Use of the
latissimus dorsi muscle as a dynamic cardiomyoplasty im-
proved the clinical status, which correlated with an obvious
reverse remodeling of the ventricular myocardium.5,24,25 To
this day, it is not clear whether this improvement was solely
due to preventing further ventricular dilation (ie, the gir-
dling effect).5
The Journal of Thoracic anIf so, cardiac function could obviously also be improved
by using a prosthetic membrane (ie, a static cardioplasty).8,9
In those studies on dogs, the ventricular size in supported
hearts was markedly reduced compared with that in unsup-
ported hearts. As a functional consequence, ejection fraction
in the supported animals remained better preserved after 4
weeks of rapid pacing (approximately 30%) than that seen
in control animals (approximately 18%).9 In the latter study,
an adynamic cardiomyoplasty (ie, unstimulated skeletal
muscle) also reduced cardiac enlargement and functional
deterioration after rapid pacing. This treatment appeared to
be more effective, perhaps because of the adaptive capabil-
ities of the skeletal muscle wrap compared with the static
myoplasty. However, cardiac binding is a less difficult and
less invasive procedure, which might be useful as an adjunct
to prevent or delay progressive ventricular dilatation in
heart failure.
In addition, the efficacy of a passive constraint to reverse
chronic chamber remodeling and adrenergic downregula-
tion was tested in the failing canine heart, in which ischemic
DCM was induced by repeated microembolizations. Re-
verse remodeling with reduced systolic wall stress and
improved adrenergic signaling was achieved by passive
external support. Hence this approach might prove useful in
the treatment of chronic heart failure.26
Similarly, the midterm results of patients with symptom-
atic heart failure suggest that ventricular constraint with
static cardioplasty might be useful for preventing further
cardiac dilation.27 Not only was ventricular remodeling
prevented in these patients, but also a reverse remodeling
was observed. The same authors later used a basal ventric-
ular constraint to also treat mitral regurgitation without
entering the heart.28
Because other clinical studies were unable to demon-
strate improved systolic function after dynamic cardiomy-
oplasty,5,29 textile meshes were developed with not only
TABLE 2. Baseline values of the no-mesh group and the
late-mesh group
No-mesh
group
Late-mesh
group P value
Heart rate (1/min) 103 8 106  7 NS
Cardiac output (L/min) 7.8 0.6 7.0 0.4 NS
LVPmax (mm Hg) 110 7 117  9 NS
dP/dtmax (mm Hg/s) 2625 149 1886 180 .011
dP/dtmin (mm Hg/s) 1778 202 1260 281 .038
LVPed (mm Hg) 5  2 15  2 .002
The contractile state (dP/dtmax) and both early (dP/dtmin) and late (LVPed)
relaxation exhibited the deleterious consequences of almost 4 weeks of
rapid pacing. NS, Not significant; LVPmax, left ventricular peak pressure;
dP/dtmax, derivative of pressure increase; dP/dtmin, derivative of pressure
decrease; LVPed, left ventricular end-diastolic pressure.static but also dynamic properties. Konertz and coworkers30
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was, because of its higher distensibility, in contrast to the
almost rigid meshes used so far.8,9 This cardiac support
device helped improve diastolic ventricular function but not
systolic function.
The results could possibly be even more promising if
wrapping of the support devices could be better standard-
ized. In one study a composite membrane was wrapped
around both ventricles plus the atria plus the venae cavae.31
In contrast, we wrapped the textile mesh only around both
ventricles, leaving the apex free. Although the tightness of
the mesh was adjusted to its effects on LV end-diastolic
pressure, the end-diastolic volume would have been more
appropriate for standardizing the wrapping procedure. In
consequence, we have used the conductance catheter and
assessed pressure-volume loops in the meantime.32
In the first part of our study, we investigated the prophy-
lactic effects of a passive-elastic cardioplasty provided by
an elastic mesh made of PVDF. This polymer is an estab-
lished biomaterial that was only recently suggested for
construction of surgical meshes.17
In fact, this new cardioplasty helped significantly reduce
systolic deterioration compared with that seen in unsup-
ported hearts. These beneficial effects might in part be due
to the mesh’s improved elastic properties that were already
described to be important.8,27,33 Furthermore, adhesions be-
tween the mesh and the epicardial layer will affect such
elastic mesh properties.19 In our two experimental groups,
we found only moderate adhesion, which we ascribe to the
properties of the PVDF mesh that reportedly exerts only
minor tissue reactions.13,17
The preservation of diastolic function in the supported
hearts in this study is in concert with that seen in former
studies on the beneficial prophylactic effects of passive
epicardial constraint on diastolic function.30
In the second part of our study, the influence of the
passive-elastic constraint on preexisting cardiac failure was
investigated. Cardiac failure was achieved by rapid ventric-
ular pacing hearts without the mesh. Tachycardia-induced
heart failure is the most commonly used experimental heart
failure model.34 Ventricular pacing at 220 to 240 beats/min
results in profound low-output, biventricular, edematous
failure in 2 to 3 weeks.35 To avoid myocardial recovery
after this procedure, we paced the hearts even longer in the
present study, namely for about 4 weeks. At the time of
reoperation, severe myocardial dilation with pleura effusion
and decreased systolic and diastolic ventricular function
was found in all animals of the late-mesh group. Indepen-
dent of our hypothesis, irrespective of whether cardiac fail-
ure after rapid pacing is reversible, LV dysfunction was
already clearly reduced after mesh grafting. Because the
mesh graft also decreased the end-diastolic pressure, we
suggest that the passive-elastic cardioplasty reduced the
1107.e6 The Journal of Thoracic and Cardiovascular Surgery ● Oend-diastolic volume and in so doing improved systolic
function in terms of CO, LV peak pressure, and dP/dtmax.
In addition, systolic and diastolic function during re-
started rapid pacing was maintained or even better com-
pared with that seen in unsupported hearts. These findings
are in contrast with those of other studies. In dogs only the
diastolic, but not the systolic, function was improved.9 In
turn, solely dynamic cardiomyoplasty was postulated to
improve both systolic and diastolic function, presenting a
promising new therapy for DCM.36
In summary, the textile cardioplasty used in this study
successfully prevented deterioration of both systolic and
diastolic myocardial function in tachycardia-induced heart
failure (ie, it exerted a prophylactic potency). Furthermore,
our passive-elastic mesh improved the consequences of
rapid pacing on hearts with experimentally induced DCM.
Thus, the mesh graft also exerted a therapeutic potency. The
beneficial effects of the textile cardioplasty are attributed to
the passive-elastic properties of the mesh and to its report-
edly minor tissue reactions.
If larger clinical studies further provide positive results
and if surgical intervention for positioning the mesh could
become less invasive, the passive-elastic cardioplasty might
become a promising alternative in the therapy of DCM, in
particular because of its surgical and economic advantages.
We greatly appreciate the secretarial help of Mrs R. Rummel.
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Evolving Technology Feindt et alFigure E1. Systolic variables of no-mesh hearts and early-mesh hearts. Although the no-mesh hearts started with
slightly reduced baseline values, the mesh reduced deterioration of systolic function during pacing. A, Cardiac
output (CO); B, peak left ventricular pressure (LVPmax); C, maximal left ventricular pressure rise (dP/dtmax). *P <
.05 vs baseline; T 25%, T 50%, T 75%, 25%, 50%, and 75% duration of rapid pacing.1107.e8 The Journal of Thoracic and Cardiovascular Surgery ● October 2005
Feindt et al Evolving TechnologyFigure E2. Diastolic variables of no-mesh hearts and early-mesh hearts. A, dP/dtmin in the no-mesh hearts and the
early-mesh hearts deteriorated significantly over time. However, the decrease in the early-mesh hearts was
relatively smaller, such that the difference between the two groups became significant at the end of the protocols.
B, The end-diastolic pressure (LVPed) significantly increased in the no-mesh hearts. At the end of the protocol,
LVPed in these hearts was significantly higher than in the early-mesh hearts. *P < .05 vs baseline;
†P < .05 vs no
mesh; T 25%, T 50%, T 75%, 25%, 50%, and 75% duration of rapid pacing.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 4 1107.e9
Evolving Technology Feindt et alFigure E3. Diastolic variables of no-mesh hearts (left) and late-mesh hearts (right). Diastolic function was
significantly decreased after about 4 weeks of rapid pacing in the no-mesh hearts. After mesh grafting and after
additional 4 weeks of pacing, early relaxation (A, dP/dtmin) had the tendency to improve, while the end-diastolic
pressure (B, LVPed) even significantly decreased. *P < .05 vs baseline; T25%, T50%, T75%, 25%, 50% and 75%
duration of rapid pacing.1107.e10 The Journal of Thoracic and Cardiovascular Surgery ● October 2005
Feindt et al Evolving TechnologyFigure E4. Systolic variables of no-mesh hearts (left) and late-mesh hearts (right). Systolic function was signifi-
cantly decreased after about 4 weeks of rapid pacing in the no-mesh hearts. Mesh grafts in these failing hearts
already improved the systolic function in terms of cardiac output (A, CO), peak LV pressure (B, LVPmax), and
contractile state (C, dP/dtmax). The meshes furthermore prevented deterioration of CO and LVPmax. DP/dtmax
significantly improved during additional 4 weeks of rapid pacing. *P < .05 vs baseline; T25%, T50%, T75%, 25%,
50% and 75% duration of rapid pacing.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 4 1107.e11
